Immediate and Mid-term Effect of a Natural Topical Product in Patients With Musculoskeletal Pain
CompletedNot applicableNCT04683263
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Musculoskeletal pain is a common affection due to ageing, sedentarism and intense exercise practice causing acute and chronic injuries. The main objective of this trial is to prove efficacy of a natural topical composition containing Arnica montana, Hypericum perforatum, Calendula officinalis, Melaleuca sp. and menthol in pain management in adults with acute or chronic pain. This randomized, double-blinded and placebo-controlled trial will include 200 patients with musculoskeletal pain, 100 in the intervention group receiving the topical formula and 100 in the placebo group, who will receive a similar formula without active ingredients. The products will be applied topically twice daily for 14 days in areas with moderate or severe pain. The study objectives are immediate and long-term pain alleviation, stiffness perception joint mobility, and general recovery perception.
Study details
- Official title
- Immediate and Mid-term Effect of a Natural Topical Product in Patients With Musculoskeletal Pain: a Randomized, Double-blinded, and Placebo-controlled Clinical Trial.
- Conditions
- Musculoskeletal Pain
- Chronic Pain
- Joint Pain
- Stiffness of Unspecified Joint, Not Elsewhere Classified
- Interventions
- Other: Placebo
- Other: Fisiocrem
- Sponsor
- Uriach Consumer Healthcare
- Collaborators
- Quironsalud
- Start date
- 2019-06-01
- Primary completion
- 2019-12-20
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- Spain
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * acute or chronic musculoskeletal pain scoring above 4 in the Visual Analogue Scale (VAS) * diagnostic of either tendinopathy, vertebral algias, sprains or symptomatic osteoarthritis Exclusion Criteria: * diagnostic in either neuropathic chronic pain, fibromyalgia or neoplasia * allergy to any ingredient in the formula
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT04683263